Incannex Healthcare Inc. (IXHL) — SEC Filings
Incannex Healthcare Inc. (IXHL) — 50 SEC filings. Latest: 8-K (Apr 22, 2026). Includes 39 8-K, 3 10-Q, 3 DEF 14A.
View Incannex Healthcare Inc. on SEC EDGAR
Overview
Incannex Healthcare Inc. (IXHL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 27, 2026: Incannex Healthcare Inc. filed an 8-K on March 27, 2026, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes a press release dated March 27, 2026, and associated graphic files, along with XBRL data.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 4 bearish, 44 neutral, 2 mixed. The dominant filing sentiment for Incannex Healthcare Inc. is neutral.
Filing Type Overview
Incannex Healthcare Inc. (IXHL) has filed 39 8-K, 1 DEFA14A, 3 10-Q, 3 DEF 14A, 2 10-K, 2 S-1/A with the SEC between Sep 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of IXHL's 46 recent filings, 6 were flagged as high-risk, 11 as medium-risk, and 29 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $-6.41M |
| EPS | $-0.02 |
| Debt-to-Equity | 0.02 |
| Cash Position | $73.28M |
| Operating Margin | -100.0% |
| Total Assets | $78.72M |
| Total Debt | $1.71M |
Key Executives
- Troy Valentine
- Joseph Swan
- Joel Latham
Industry Context
Incannex Healthcare operates in the highly competitive and regulated pharmaceutical and biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies in this space often rely on substantial funding rounds to finance clinical trials and navigate the path to commercialization.
Top Tags
corporate-filing (12) · sec-filing (10) · 8-K (8) · 8-k (6) · filing (5) · pharmaceuticals (5) · material-agreement (5) · delisting (4) · reporting (4) · corporate-update (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $73.28M | Increased from $15.04M at June 30, 2025, providing significant liquidity. |
| Net loss | $6.41M | Widened from $5.42M in Q3 2024, indicating increasing unprofitability. |
| Proceeds from share issuance | $69.47M | Primary driver of increased cash and stockholders' equity. |
| Revenue from customers | $0 | Decreased from $74K in Q3 2024, highlighting pre-commercial stage. |
| General and administrative expenses | $5.67M | Increased from $3.43M in Q3 2024, contributing to higher operating costs. |
| Research and development expenses | $1.12M | Decreased from $2.90M in Q3 2024. |
| Total stockholders' equity | $77.01M | Significantly increased from $13.39M at June 30, 2025, due to share issuance. |
| Shares issued and outstanding | 347,705,507 | Increased from 194,379,996 shares at June 30, 2025, reflecting dilution from share issuance. |
| Shares of Common Stock Outstanding | 347,705,507 | Entitled to vote as of the Record Date, October 24, 2025 |
| Class II Directors | 2 | To be elected for three-year terms expiring in 2028 |
| Director Term Expiration Year | 2028 | New Class II directors will serve until this year |
| Fiscal Year for Auditor Appointment | 2026 | Grant Thornton Audit Pty Ltd appointed for fiscal year ending June 30, 2026 |
| Record Date | October 24, 2025 | Date for determining stockholders entitled to vote at the Annual Meeting |
| Annual Meeting Date | December 18, 2025 | Date of the 2025 Annual Meeting of Stockholders |
| Proxy Materials Distribution Start Date | October 31, 2025 | Date Incannex intends to begin sending Internet Availability Notice |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Incannex Healthcare Inc. (IXHL)?
Incannex Healthcare Inc. has 50 recent SEC filings from Sep 2024 to Apr 2026, including 39 8-K, 3 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IXHL filings?
Across 50 filings, the sentiment breakdown is: 4 bearish, 44 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Incannex Healthcare Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Incannex Healthcare Inc. (IXHL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Incannex Healthcare Inc.?
Key financial highlights from Incannex Healthcare Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IXHL?
The investment thesis for IXHL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Incannex Healthcare Inc.?
Key executives identified across Incannex Healthcare Inc.'s filings include Troy Valentine, Joseph Swan, Joel Latham.
What are the main risk factors for Incannex Healthcare Inc. stock?
Of IXHL's 46 assessed filings, 6 were flagged high-risk, 11 medium-risk, and 29 low-risk.
What are recent predictions and forward guidance from Incannex Healthcare Inc.?
Forward guidance and predictions for Incannex Healthcare Inc. are extracted from SEC filings as they are enriched.